Literature DB >> 18678362

[Parapharyngeal tumors: diagnosis and treatment].

F Bouilloud1, F Jégoux, A Caze, B Godey, G Le Clech.   

Abstract

OBJECTIVES: Parapharyngeal space tumors are rare and usually benign. Their treatment is surgical and many approaches have been described. We report our experience in managing these neoplasms. Two points are developed more fully: the correlation between imaging and surgical observation and the reliability of the cervical approach.
MATERIAL AND METHODS: A retrospective review of primary parapharyngeal space tumors treated at the Rennes University Hospital between 1992 and 2004 is presented. Nine patients were included, all treated surgically with a cervical approach without parotidectomy.
RESULTS: Eight MR imaging and seven CT scans were done. Two retrostyloid tumors and six prestyloid tumors, all independent of the deep lobe of the parotid gland, were found. They were benign in all cases (five salivary tumors and four schwannomas). Two patients treated for a pleomorphic adenoma presented recurrence and were reoperated successfully. The average follow-up was 66 months. None of the patients died. Definitive postoperative complications occurred only for neurogenic tumors.
CONCLUSION: The cervical approach is safe and allows the surgical excision of retrostyloid and prestyloid tumors, independent of the deep lobe of the parotid gland. Large tumor (8cm in our study) excision can be done with few complications. An attentive study of preoperative imaging is necessary to choose the best surgical approach.

Entities:  

Mesh:

Year:  2008        PMID: 18678362     DOI: 10.1016/j.aorl.2008.05.001

Source DB:  PubMed          Journal:  Ann Otolaryngol Chir Cervicofac        ISSN: 0003-438X


  1 in total

1.  Prestyloid compartment of the parapharyngeal space: a histological study using late-stage human fetuses.

Authors:  Yukio Katori; Tatsuaki Kawase; Kwang Ho Cho; Hiroshi Abe; Jose Francisco Rodríguez-Vázquez; Gen Murakami; Shinichi Abe
Journal:  Surg Radiol Anat       Date:  2012-05-11       Impact factor: 1.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.